详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta-analysis

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, West China Hospital Sichuan University Chengdu China. [2]Institute of Urology, West China Hospital Sichuan University Chengdu China.

出处：

DOI：

关键词： cancer treatment mRNA vaccines objective response rate safety solid tumor

摘要：

Tumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines could promote a clinical benefit to advanced cancer patients is highly unknown. PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023. Random effects models were employed. Clinical benefit (objective response rate [ORR], disease control rate [DCR], 1-year/2-year progression-free survival [PFS], and overall survival [OS]) and safety (vaccine-related grade 3-5 adverse events [AEs]) were evaluated. Overall, 984 patients (32 trials) were enrolled. The most typical cancer types were melanoma (13 trials), non-small cell lung cancer (5 trials), renal cell carcinoma (4 trials), and prostate adenocarcinoma (4 trials). The pooled ORR and DCR estimates were 10.0% (95%CI, 4.6-17.0%) and 34.6% (95%CI, 24.1-45.9%). The estimates for 1-year and 2-year PFS were 38.4% (95%CI, 24.8-53.0%) and 20.0% (95%CI, 10.4-31.7%), respectively. The estimates for 1-year and 2-year OS were 75.3% (95%CI, 62.4-86.3%) and 45.5% (95%CI, 34.0-57.2%), respectively. The estimate for vaccine-related grade 3-5 AEs was 1.0% (95%CI, 0.2-2.4%). Conclusively, mRNA vaccines seem to demonstrate modest clinical response rates, with acceptable survival rates and rare grade 3-5 AEs.© 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验

最新[2023]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Urology, West China Hospital Sichuan University Chengdu China. [2]Institute of Urology, West China Hospital Sichuan University Chengdu China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Urology, West China Hospital Sichuan University Chengdu China. [2]Institute of Urology, West China Hospital Sichuan University Chengdu China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Letter to the Editor: mRNA Vaccines in Urological Malignancies [2]Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer [3]A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma [4]Efficient signal sequence of mRNA vaccines enhances the antigen expression to expand the immune protection against viral infection [5]Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities [6]Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges [7]Frequent microsatellite instability in Chinese solid tumor patients [8]Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial [9]Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients [10]Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis.